ProtoKinetix Secures Funding but Faces Ongoing Financial Losses and Operational Challenges

Company Overview: ProtoKinetix, Incorporated (OTCBB: PKTX) is a development stage biotechnology company focused on researching synthetic antifreeze glycoproteins (AAGP) intended to enhance human health care. The Company is actively working to commercialize its proprietary technologies.

Recent Developments: In Q1 2025, ProtoKinetix issued 13.2 million shares as part of a private placement yielding $132,000, demonstrating investor confidence in the company's research initiatives.

Income Statement Highlights:

• Total operating expenses: $97,690 (Q1 2025) vs. $92,026 (Q1 2024), reflecting a year-over-year increase of $5,664.
• Amortization expenses: Increased slightly to $12,662, from $11,317.
• General and administrative expenses: Remained stable, increasing marginally by $623 to $14,748.
• Professional fees: Increased significantly by $6,511, totaling $36,470, due to rising auditing and legal costs.
• Research and development costs: Decreased to $33,810 from $36,625, showing a focus on cost management.
• Net loss for the period: $97,690 (Q1 2025) compared to $92,026 (Q1 2024), indicating ongoing challenges in achieving profitability.

Assets and Liabilities:

• Total assets: $528,625 (as of March 31, 2025), up from $466,137 at the end of 2024.
• Total liabilities: $152,225, an increase from $124,047 at year-end 2024, primarily due to higher accounts payable and accrued liabilities.
• Total stockholders' equity: Increased to $376,400, from $342,090, due to equity financing activities.

Cash Flow Summary:

• Net cash used in operating activities: $51,970 (2025), improved from $57,836 (2024).
• Net cash used in investing activities: Increased to $25,856, reflecting higher spending on intangible assets compared to $9,736 in 2024.
• Net cash from financing activities: Increased to $132,000, reflecting successful funding efforts through private placements.

Positive Aspects:

• Successful completion of a private placement shows ongoing investor support.
• Increased stockholders' equity indicates a financial strengthening of the Company.
• Reduction in cash used in operating activities implies better cash flow management.

Negative Aspects:

• Continued net losses reflect a lack of revenue generation, raising concerns over sustainability.
• Increasing liabilities could strain future cash flows, necessitating further financing.
• Dependence on external financing presents risks given market volatility and economic uncertainties.

Conclusion: ProtoKinetix, Inc. continues to pursue its mission with a focus on developing its unique AAGP technology. While the Company's recent capital raises highlight investor trust, the ongoing financial losses and operational challenges remain significant hurdles. Stakeholders should monitor the Company's progress especially in forming strategic partnerships for future funding and product development.